Schizophrenia News

The prevalence of mental disorders has been on the rise and remains a significant leading cause of disease burden worldwide, according to a 30-year global systematic analysis published in The Lancet Psychiatry.

Findings of a genome-wide association study suggested a heritable component of treatment-resistant schizophrenia, according to results published in JAMA Psychiatry.

Neuroscience specialty pharmaceutical company OWP Pharmaceuticals Inc. has partnered with Eversana, a provider of global services to the life sciences industry, to launch oral liquid formulations for treating neuroscience disorders.

Likelihood of inheritance for hypomania, which may lead to bipolar disorder or other mental illnesses, is greater in male twins than in female twins, according to a Swedish cohort study published in JAMA Psychiatry.

Healio Psychiatry’s five most-viewed stories of the year highlight a study on omega-3 supplementation and stress-related accelerated aging, research into the benefits of cannabidiol for frontline health care workers and data on the link between OCD and increased risk for dementia/Alzheimer’s disease.

Vitamin D supplementation did not appear linked to mental health or metabolic outcomes at 6 months in people with first-episode psychosis, according to results of a randomized clinical trial published in JAMA Network Open.

People with schizophrenia spectrum disorders appeared to have increased risk for perpetrating violent outcomes compared with community control individuals, according to a systematic review and meta-analysis published in JAMA Psychiatry.

Individuals with schizophrenia who died by suicide were more likely to be older, have previous suicide attempts and be women, according to data published in Psychiatry Research.

Results of a 5-year study in Japan suggest pulmonary embolism may be a major cause of sudden cardiac arrest among patients with psychiatric disorders.

A single-arm, single-blind, phase 2a study of the neuromodulating drug RL-007, initiated by biopharmaceutical company atai Life Sciences, revealed its effectiveness in improving cognitive function and awareness in patients with schizophrenia.